Overview

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-26
Target enrollment:
Participant gender:
Summary
A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca